Table 1.
Clinical Characteristics of the Patients Who Underwent PARTO
| Variable | Total | Child-Pugh A | Child-Pugh B/C | p-value |
|---|---|---|---|---|
| No. | 54 | 26 | 28 | |
| Age, yr | 56.60±10.26 | 57.04±8.72 | 56.21±11.64 | 0.771 |
| Sex | 0.382 | |||
| Male | 37 (68.5) | 16 (61.5) | 21 (75.0) | |
| Female | 17 (31.5) | 10 (38.5) | 7 (25.0) | |
| Etiology | 0.450 | |||
| Alcohol | 24 (44.4) | 10 (38.5) | 14 (50.0) | |
| HBV | 14 (25.9) | 8 (30.8) | 6 (21.4) | |
| HCV | 2 (3.7) | 2 (7.7) | 0 | |
| Others | 14 (25.9) | 6 (23.1) | 8 (28.6) | |
| MELD score | 11.46±4.35 | 9.35±2.61 | 13.5±4.67 | <0.001* |
| Gastric varix type | 0.417 | |||
| GOV1 | 12 (22.2) | 5 (19.2) | 7 (25.0) | |
| GOV2 | 36 (66.7) | 17 (65.4) | 19 (67.9) | |
| Others | 5 (9.3) | 4 (15.4) | 1 (3.6) | |
| None | 1 (1.9) | 0 | 1 (3.6) | |
| PARTO indication | 0.574 | |||
| Active bleeding | 11 (20.4) | 4 (15.4) | 7 (25.0) | |
| Recent bleeding | 13 (24.1) | 6 (23.1) | 7 (25.0) | |
| Primary prophylaxis | 29 (53.7) | 16 (61.5) | 13 (46.4) | |
| HE control | 1 (1.9) | 0 | 1 (3.6) | |
| EV change after PARTO | 0.572 | |||
| Deterioration | 26 (53.1) | 11 (47.8) | 15 (57.7) | |
| No change | 23 (46.9) | 12 (52.2) | 11 (42.3) | |
| Liver function improvement after PARTO | 0.02* | |||
| Improvement | 17 (31.5) | 4 (15.4) | 13 (46.4) | |
| No change or deterioration | 37 (68.5) | 22 (84.6) | 15 (53.6) |
Data are presented as mean±SD or number (%).
PARTO, plug-assisted retrograde transvenous obliteration; HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, Model for End-Stage Liver Disease; GOV1, gastroesophageal varix type 1; GOV2, gastroesophageal varix type 2; HE, hepatic encephalopathy; EV, esophageal varices.
*Statistically significant, p<0.05.